A more in-depth take a look at vaccine power revealed a shocking hyperlink to mind well being.
A routine go to to a public well being workplace led to an sudden scientific perception, one that will reshape how researchers take into consideration stopping Alzheimer’s illness.
A brand new examine from UTHealth Houston reviews that older adults who obtain the next dose of the influenza vaccine could have a considerably decrease danger of creating Alzheimer’s illness in contrast to those that obtain the usual dose.
The outcomes had been revealed in Neurology.
Alzheimer’s illness is the main explanation for dementia, affecting greater than 7 million Americans age 65 and older as of 2025. That represents about 1 in 9 folks on this age group, and the quantity is projected to greater than double by 2050.
Earlier research from 2022, led by Paul Schulz, MD, a professor of neurology at McGovern Medical School at UTHealth Houston and director of the Neurocognitive Disorders Center, discovered that folks age 65 and older had a decrease danger of Alzheimer’s illness in the event that they obtained a flu vaccine.
Now, three years later, Schulz and his workforce report that the discount in danger is even better amongst those that obtain the next dose of the vaccine.
A Question That Sparked New Research
“The public health department had seen our vaccine research and asked if I could come down to talk to them about it,” stated Schulz, who’s the senior creator of the examine and the Rick McCord Professor in Neurology and Umphrey Family Professor in Neurodegenerative Diseases at McGovern Medical School. “We went through the findings, and they asked if there was a difference with different dosages; I was confused.”
As folks attain age 65, the immune system turns into much less efficient at preventing infections. For this purpose, the CDC recommends a high-dose flu vaccine for adults on this age group, which is 4 instances stronger than the usual model given to the final inhabitants.
“I was stunned that, as a physician, I didn’t know a higher dose was offered,” Schulz stated.
Vaccine Use and Gaps in Knowledge
Flu vaccination is advisable for everybody, however influenza may cause extra critical issues in folks with Alzheimer’s illness.
Before 2022, the CDC didn’t favor one intramuscular flu vaccine over one other for adults age 65 and older. The fundamental advice was merely to get vaccinated every year, whatever the formulation. Previous UTHealth Houston analysis confirmed that inactivated flu vaccines had been linked to a 40% decrease danger of Alzheimer’s illness, however no research had examined whether or not larger doses may present further safety.
Schulz additionally famous that the getting older inhabitants has strained the availability of high-dose vaccines in some areas. As a consequence, some people nonetheless obtain the usual dose.
Comparing High- and Standard-Dose Vaccines
“So we started looking, and sure enough, we were able to put together thousands and thousands of people over the age of 65 who got the high- or low-dose vaccine. They’re more at risk for Alzheimer’s than anybody else, of course, because it’s age-related and we could look at high-dose versus low-dose and see if there was a difference,” Schulz stated.
The workforce analyzed information from practically 200,000 adults age 65 and older, together with each women and men. The outcomes confirmed that those that obtained the high-dose influenza vaccine had a decrease danger of Alzheimer’s illness than those that obtained the usual dose. The protecting impact was extra pronounced in ladies.
Compared to the standard-dose flu vaccine, which was related to a 40% discount in Alzheimer’s danger, the high-dose vaccine was linked to practically a 55% discount in danger amongst adults age 65 and older.
Reference: “Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination” by Avram Samuel Bukhbinder, Yaobin Ling, Lauren Jhin, Elizabeth He, Kristofer Harris, Mya Rodriguez, Jenna Thomas, Gabriela Cruz, Kamal Phelps, Yejin Kim, Luyao Chen, Xiaoqian Jiang and Paul E. Schulz, 1 April 2026, Neurology.
DOI: 10.1212/WNL.0000000000214782
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
